Jayson L Parker

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. doi request reprint Impact of biomarkers on clinical trial risk in breast cancer
    Jayson L Parker
    Department of Biology, University of Toronto, Mississauga, ON, Canada
    Breast Cancer Res Treat 136:179-85. 2012
  2. ncbi request reprint The success rate of new drug development in clinical trials: Crohn's disease
    Jayson L Parker
    Department of Biology, University of Toronto, Toronto, Canada
    J Pharm Pharm Sci 13:191-7. 2010
  3. ncbi request reprint Clinical trial risk in Non-Hodgkin's lymphoma: endpoint and target selection
    Jayson L Parker
    Biology Department, Master of Biotechnology Program, University of Toronto, Toronto, ON
    J Pharm Pharm Sci 14:227-35. 2011
  4. ncbi request reprint Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise
    Alessandro Tenuta
    Department of Management, University of Toronto at Mississauga, Toronto, ON, Canada
    BJU Int 113:E82-9. 2014
  5. doi request reprint Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer
    Adam Falconi
    Department of Pharmacy, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada HCor Onco Cancer Center, Sao Paulo, SP, Brazil and OncoclĂ­nicas do Brasil, Belo Horizonte, MG, Brazil Johns Hopkins University School of Medicine, Baltimore, Maryland and Department of Biology, University of Toronto at Mississauga, Toronto, Ontario, Canada
    J Thorac Oncol 9:163-9. 2014
  6. doi request reprint Risk of failure of a clinical drug trial in patients with moderate to severe rheumatoid arthritis
    Kavisha S Jayasundara
    University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 39:2066-70. 2012

Collaborators

Detail Information

Publications6

  1. doi request reprint Impact of biomarkers on clinical trial risk in breast cancer
    Jayson L Parker
    Department of Biology, University of Toronto, Mississauga, ON, Canada
    Breast Cancer Res Treat 136:179-85. 2012
    ..However, these data have to be evaluated in a context in which studies combining a novel drug with a novel biomarker not yet recognized by the FDA may actually increase clinical trial risk...
  2. ncbi request reprint The success rate of new drug development in clinical trials: Crohn's disease
    Jayson L Parker
    Department of Biology, University of Toronto, Toronto, Canada
    J Pharm Pharm Sci 13:191-7. 2010
    ..To determine the risk of drug failure during clinical trial testing in Crohn's disease and determine what steps can be taken to improve outcomes. This is the first study to quantify such risk for a single disease...
  3. ncbi request reprint Clinical trial risk in Non-Hodgkin's lymphoma: endpoint and target selection
    Jayson L Parker
    Biology Department, Master of Biotechnology Program, University of Toronto, Toronto, ON
    J Pharm Pharm Sci 14:227-35. 2011
    ..To quantify the clinical trial risk of new drug development in Non-Hodgkin's lymphoma (NHL). Risk estimates for this disease have not been reported before...
  4. ncbi request reprint Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise
    Alessandro Tenuta
    Department of Management, University of Toronto at Mississauga, Toronto, ON, Canada
    BJU Int 113:E82-9. 2014
    ..To determine the risk of failure during drug development in castration-resistant prostate cancer (CRPC) and to identify factors that could improve outcomes...
  5. doi request reprint Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer
    Adam Falconi
    Department of Pharmacy, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada HCor Onco Cancer Center, Sao Paulo, SP, Brazil and OncoclĂ­nicas do Brasil, Belo Horizonte, MG, Brazil Johns Hopkins University School of Medicine, Baltimore, Maryland and Department of Biology, University of Toronto at Mississauga, Toronto, Ontario, Canada
    J Thorac Oncol 9:163-9. 2014
    ..This study analyzed the risk of clinical trial failure during non-small-cell lung cancer (NSCLC) drug development between 1998 and January 2012. We also looked for factors that impacted clinical trial risk in NSCLC...
  6. doi request reprint Risk of failure of a clinical drug trial in patients with moderate to severe rheumatoid arthritis
    Kavisha S Jayasundara
    University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 39:2066-70. 2012
    ..We conducted a systematic review to determine the risk of drug failure in clinical testing with patients with moderate to severe rheumatoid arthritis (RA)...